Skip to content

New Data At ASCO and EHA 2026 Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

Read More
  • Investors
  • Join Our Team
Logo for Adaptive Biotechnologies
    • About
    • clonoSEQ MRD Test
    • Clinical Portfolio & Pipeline
    • Medical Information
    • Publications
    • Clinical Diagnostics
    • clonoSEQ
    • Biopharma Solutions
    • Biopharma Services
    • About
      • Immune Medicine Platform
      • The Adaptive Immune System
      • Publications
    • Blog
      • Adaptive Earns Cornerstone Recognition for LGBTQ+ Workplace Inclusion in HRC’s 2025 Corporate Equality Index
      • Jim’s Journey: The Power of Collaboration in Blood Cancer Care
      • Predicting T Cell Recognition: New Insights from Large-Scale Activation Data
      • See all posts
    • Media
      • Press Releases
      • Media Resources
      • Events
      • Conferences & Events
    • About Us
      • Who We Are
      • Our Story
      • Innovation Timeline
      • Leadership
      • Licenses and Accreditation
      • Corporate Social Responsibility
    • Careers
      • Career Listings
      • Connect
      • Contact
      • Investors
      • Investor Relations
      • Newsroom

Years: 2017

Adaptive Partners with Microsoft to Map the Human Immune System

Adaptive partners with Microsoft, combining their AI and machine-learning capabilities with our platform to map TCRs to the diseases they detect at scale. The goal is to develop blood tests for early and accurate detection of many diseases.

Powering the Age of Immune Medicine
Contact Us
  • About Us
  • HIPAA Notice
  • Sitemap
  • Careers
  • View our instagram'
  • View our facebook'
  • View our twitter'
  • View our linkedin'
  • Privacy Policy
  • Notice at Collection
  • Cookie Policy
  • Do Not Sell or Share My Info
© Adaptive Biotechnologies. All Rights Reserved.